Lymphoma Clinical Trials and Research

Our lymphoma program is often among the first in the nation to test new medications for lymphoma via clinical trials.

More than ever before, physicians and researchers are working together to quickly and effectively translate basic research to patient care. The University of Chicago Medicine lymphoma research program focuses on:

Clinical Trials: Access to the Latest Therapies

Because our lymphoma specialists are nationally renowned for their clinical and research expertise, our program is often among the first in the country to test new medications via clinical trials sponsored by the National Cancer Institute and pharmaceutical companies. At any given time, we offer between 15 and 20 clinical trials -- including Phase 1 and Phase 2 studies -- for common to rare subtypes of lymphoma at various stages. Many of our trials use targeted therapies that attack specific cancer pathways.

Lymphoma Biobank

The Lymphoma Biobank at the University of Chicago Medicine is an innovative new program that links epidemiology (the study of how disease spreads and can be controlled) to malignant lymphoma tissue. The Biobank collects and stores donated biospecimens (e.g. tissue, urine, blood) and connects it to personal and medical information. Biobank researchers will examine how lifestyle, occupation, environment and genes affect lymphoma. The goal of the program is to increase understanding of how to prevent, diagnose and treat lymphoma.

National and International Leaders in Cancer Research

Our physicians are recognized leaders in several major national organizations dedicated to cancer research including: